# Cumulus Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cumulus-oncology

- Industry: Healthcare Specialists
- Headquarters: Edinburgh, UK
- Website: www.cumulusoncology.com
- Total disclosed funding: $11M
- Latest round: Seed (Dec 20, 2023)
- Investors on record: 2

## About

Cumulus Oncology Limited, based in the UK, focuses on developing and commercializing innovative therapies for oncology while connecting various stages of the drug development process to enhance clinical success rates.Cumulus Oncology Limited specializes in oncology therapy development and was founded in 2017. The company is headquartered in Edinburgh, UK. Clare Wareing is the founder, who has a history in launching other ventures within the biotech sector. Cumulus has successfully closed 3 deals, with the most recent funding round being a SEED round on December 20, 2023, where they raised GBP 8.999 million led by Eos Advisory and supported by Scottish National Investment Bank. The total amount raised by the company stands at GBP 8.999 million, with a current valuation of GBP 26.236 million.Cumulus Oncology specializes in the development and commercialization of innovative oncology therapies by leveraging a unique approach that connects various stages of the drug development process, from research to market entry. Their core offering involves identifying high-potential assets within oncology, utilizing stringent early-stage evaluation criteria, and targeting patient sub-groups to optimize clinical success. The company collaborates with a diverse array of asset holders, including academic institutions and commercial entities, to ensure that effective scientific innovations are effectively translated into viable therapies. Cumulus Oncology primarily operates within the global biotechnology market, focusing on regions that are advancing cancer research and therapy development.Cumulus Oncology generates revenue through a multifaceted business model that incorporates partnerships, co-development agreements, and licensing arrangements. The company engages with clients, including biotechnology firms and research institutions, to facilitate the advancement of oncology assets into market-ready therapies. Transactions typically involve structured agreements where Cumulus provides expertise in drug development and commercialization in exchange for equity stakes or revenue-sharing models based on successful outcomes. These partnerships allow Cumulus to leverage its scientific and entrepreneurial expertise while driving innovation in cancer treatment. The company’s revenue streams are closely tied to the successful development and commercialization of the oncology therapies they support, with a focus on creating new companies and enhancing shareholder value.Cumulus Oncology plans to utilize its recent SEED funding of GBP 8.999 million, raised in December 2023, to support growth, expansion, and the development of new cancer treatments. Specific strategies include launching upcoming oncology products and exploring new markets, with a focus on enhancing their presence in regions advancing cancer research. The company aims to achieve these objectives within the next few years, leveraging this funding to improve their operational capabilities and foster innovation in cancer therapy.

## Funding rounds

- Seed, Dec 20, 2023, $11M — Scottish National Investment Bank, Eos

## Investors

- Scottish National Investment Bank — Seed
- Eos — Seed